News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Furiex Pharmaceuticals, Inc. (FURX) Announces Acceptance To Late-Breaking Abstract Session At Digestive Disease Week 2014


4/4/2014 7:06:50 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced that results from its two Phase III clinical trials of eluxadoline in patients with diarrhea-predominant irritable bowel syndrome will be presented in a Late-Breaking Abstract Session at Digestive Disease Week (DDW) 2014, to be held May 3-6 at McCormick Place in Chicago, IL.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES